BridgeBio Pharma, Inc. (BBIO)

Name: BridgeBio Pharma, Inc. (BBIO) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001743881 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, BridgeBio Pharma, Inc. reported revenue of $502.08M. Revenue grew 126.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $713.07M.

Key ratios (year ended 2025-12-31)

-104.2%

Operating margin

-146.0%

Net margin

126.3%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-13

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Revenue	$713.07M	$502.08M	$221.90M	$9.30M	$77.65M	$69.72M	$8.25M	$40.56M	n/a	n/a
Cost of Revenue	$39.66M	$20.96M	$3.88M	$2.45M	$3.43M	$3.11M	n/a	n/a	n/a	n/a
Gross Profit (computed)	$673.41M	n/a	n/a	$6.86M	n/a	n/a	n/a	n/a	n/a	n/a
R&D Expense	$505.38M	$451.95M	$506.46M	$455.71M	$399.46M	$451.02M	$337.05M	$209.95M	$140.07M	$30.56M
Operating Income	-$497.80M	-$523.41M	-$592.97M	-$607.37M	-$512.20M	-$576.63M	-$474.48M	-$266.24M	-$183.66M	-$43.86M
Depreciation & Amortization	$5.07M	$5.43M	$6.08M	$6.49M	$6.77M	$5.84M	$1.46M	$859.0K	n/a	n/a
EBITDA	-$492.72M	-$517.98M	-$586.90M	-$600.88M	-$505.43M	-$570.79M	-$473.03M	-$265.38M	n/a	n/a
Net Income	-$702.02M	-$732.94M	-$543.35M	-$653.25M	-$484.65M	-$586.45M	-$505.49M	-$288.58M	-$169.45M	-$43.83M
EPS (Diluted)	n/a	-$3.78	-$2.88	-$3.95	-$3.26	-$3.90	-$3.80	n/a	n/a	n/a
Total Assets	$1.22B	$936.02M	$919.34M	$546.38M	$623.04M	$1.01B	$703.59M	$631.68M	$464.94M	n/a
Total Liabilities	$3.72B	$3.01B	$2.38B	$1.89B	$1.87B	$1.88B	$595.70M	$155.70M	$87.58M	n/a
Long-Term Debt	$2.65B	$2.01B	n/a	n/a	n/a	n/a	$93.88M	$95.37M	n/a	n/a
Shareholders' Equity	-$2.52B	-$2.09B	-$1.47B	-$1.35B	-$1.25B	-$870.41M	$57.91M	$408.45M	$314.88M	$85.85M
Cash & Equivalents	$677.91M	$570.12M	$681.10M	$375.94M	$376.69M	$393.77M	$356.08M	$363.77M	$436.09M	$92.00M
Operating Cash Flow	-$434.37M	-$445.91M	-$520.73M	-$527.72M	-$419.49M	-$497.93M	-$399.71M	-$253.59M	-$136.64M	-$40.49M
Capital Expenditures	$1.01M	$1.10M	$933.0K	$1.31M	$4.82M	$13.25M	$7.52M	$2.64M	$2.18M	$464.0K
Free Cash Flow	-$435.39M	-$447.01M	-$521.66M	-$529.03M	-$424.31M	-$511.18M	-$407.23M	-$256.23M	-$138.82M	-$40.95M
Share Repurchases	$210.00M	$48.28M	$0	$0	$0	$200.00M	$75.00M	n/a	n/a	n/a
Dividends Paid	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$997.0K	n/a	$1.15M
Shares Outstanding	195.28M	194.77M	190.04M	175.08M	150.63M	147.34M	122.85M	123.66M	92.06M	n/a
Weighted Average Diluted Shares	n/a	191.53M	186.08M	162.79M	147.47M	144.36M	118.00M	n/a	n/a	n/a
EPS (Basic)	n/a	-$3.78	-$2.88	-$3.95	-$3.26	-$3.90	-$3.80	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView